



> Return address PO Box 320, 1110 AH Diemen

To the State Secretary of
Health, Welfare and Sport
PO Box 20350
2500 EJ THE HAGUE

2021046502

Date 1 December 2021
Subject GVS advice tirbanibulin (Klisyri®)

**National Health Care
Institute**

Care
Medicinal Products

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Contact

Ms J.M. van der Waal
T +31 (0)6 120 017 28

Our reference

2021046502

Dear Mr Blokhuis,

In your letter of 12 October 2021 (CIBG-21-02629), you asked the National Health Care Institute to assess whether the medicinal product tirbanibulin (Klisyri®) can be included in the Medicine Reimbursement System (GVS).

Tirbanibulin is available as an ointment with 10 mg/g (1%) tirbanibulin as active ingredient. Each sachet contains 2.5 mg tirbanibulin in 250 mg of ointment. It is indicated for the topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. We have handled this request using a marginal assessment. The considerations are included in the GVS report attached to this letter.

Conclusion of the marginal assessment

Based on the criteria for interchangeability, it can be concluded that tirbanibulin (Klisyri®) is interchangeable with the other medicinal products in the GVS cluster OD06BBADC V, which includes: 5-fluorouracil, imiquimod and methyl aminolevulinate.

Advice

We advise you to include tirbanibulin on List 1A in cluster OD06BBADC V of the GVS with 5-fluorouracil, imiquimod and methyl aminolevulinate. The standard dose for tirbanibulin can be set at 0.014 pcs per day.

Yours sincerely,

Sjaak Wijma
Chair of the Executive Board